What dose of Wegovy is equivalent to 7.5 mg Mounjaro?

Is there a true dose-equivalent between 7.5 mg Mounjaro and any Wegovy dose?

Strictly speaking, no. Mounjaro (tirzepatide) activates two receptors (GIP and GLP-1) while Wegovy (semaglutide) targets GLP-1 alone. Because the pharmacology differs, no conversion chart exists in clinical guidance, and neither the NHS nor NICE has published an equivalence table. The question how Mounjaro-to-Wegovy dose conversion works comes up often, and the consistent answer from prescribers is that position in the titration schedule is the nearest proxy, not weight of active ingredient.

Tirzepatide's UK schedule runs from 2.5 mg through to 15 mg across six doses, each typically held for four weeks before stepping up. At 7.5 mg a patient is roughly halfway through that ladder. Wegovy's injection schedule reaches maintenance at 2.4 mg (or, since April 2026, up to 7.2 mg for those on the new single-dose pen approved by the MHRA). Positionally, 7.5 mg Mounjaro sits at a mid-titration point, broadly aligned in treatment duration with semaglutide around 1.7 mg, the fourth rung on the standard Wegovy ladder. That parallel is rough and should not be used to self-direct a switch. A prescriber considers BMI, tolerance, weight-loss trajectory and history before recommending any dose on either medicine.

For the specific question of what Wegovy dose is equivalent to 7.5 mg of Mounjaro, the most defensible answer remains: there is no direct equivalent, and if you are trying to understand what a Wegovy equivalent to Mounjaro 7.5 looks like in practice, the starting dose on any switch is a clinical call, not a calculation.

What do the trial results tell us about relative potency at these dose levels?

The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed average body-weight reductions of around 20–21% at tirzepatide 15 mg over 72 weeks in adults with obesity. STEP 1, the equivalent semaglutide trial, reported roughly 15% average reduction at 2.4 mg over 68 weeks. Neither trial evaluated 7.5 mg tirzepatide against a specific Wegovy dose in isolation, so head-to-head data at this particular dose point does not exist in the published literature.

The table below sets out what is known from trial data and licensed schedules, not equivalences, but reference points.

SURMOUNT-5, published in 2025, directly compared both medicines in adults with obesity and no diabetes over 72 weeks. Tirzepatide produced a greater average weight reduction than semaglutide 2.4 mg, though the 7.2 mg semaglutide dose narrows that gap considerably. Mid-titration comparisons (7.5 mg versus any semaglutide rung) were not the trial's focus.

What if I want to switch from 7.5 mg Mounjaro to Wegovy, or vice versa?

Switching between GLP-1 medicines mid-treatment is not uncommon. Supply constraints, tolerability, or a clinical decision to try the alternative all prompt it. The key points are practical. First, a prescriber needs to review your current weight, dose history and any side-effect pattern before recommending a starting dose on the new medicine. Starting too high risks GI side effects; starting too low may feel like a step backwards in progress. Second, timing matters more than people expect, switching partway through a titration ladder means the new medicine's tolerability doses serve a genuine settling-in purpose again, even if you've been injecting for months.

If your question is really about which Mounjaro dose is comparable to a given Wegovy dose in the other direction, the same logic applies: positional alignment is a starting frame, individual clinical assessment is the method. Prescribers at nume review the full picture before confirming any switch and the dose to restart on. Worth noting: if you're planning to order before a bank holiday or over a quiet patch in the calendar, same-day dispatch requires the order in before 12 pm on a working day, plan accordingly so your supply doesn't lapse mid-switch.

Our prescribers are available through the free consultation to walk through your specific situation. There is no obligation, and the review happens the same day.

Which medicine is the right choice for you at this point?

The evidence shows both medicines are effective for weight management in adults who meet the licensed criteria. Mounjaro's dual-receptor action produces larger average losses in the published trials; Wegovy's longer track record and the new 7.2 mg approval have strengthened its position. Neither is universally the better fit. Tolerability, how far through your titration you are, your weight-related conditions, and whether you've tried one already all shape the decision.

The NICE appraisal of tirzepatide (TA1026) and the equivalent assessment for semaglutide (TA875) both set out clinical criteria; private prescribing follows the licensed indications. A prescriber looks at the whole picture, not just a dose number. Which suits you is a clinical decision our prescribers make with you, informed by your history and goals, not by a conversion table. You can read more about how the two medicines compare overall on our Wegovy vs Mounjaro page, or explore weight-loss treatment options more broadly. If you'd like to talk through a switch or a new start, start your free consultation and a prescriber will review your case the same day.